

Krakow, 21<sup>st</sup> September 2023

## REQUEST FOR QUOTATION No. ABM-21 09 2023 F

In connection with the planned implementation by Ryvu Therapeutics S.A. of the project ‘The conduct of a phase II, multicentre, open-label clinical trial (RIVER-81) evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior therapy with venetoclax and a hypomethylating agent’ (the ‘Project’) under the Competition: Development of targeted or personalized medicine based on therapeutic products based on nucleic acids and small-molecule compounds ABM/2022/6 organized by the Medical Research Agency, Ryvu Therapeutics S.A. invites quotes for the execution of the following defined order description.

### I. ORDERING PARTY

Ryvu Therapeutics S.A.  
 Sternbacha 2, 30-394 Krakow, Poland  
 EU VAT PL6792942955

### II. ORDER DESCRIPTION

In the scope of the order description is the sale and delivery of the following products:

#### Part 1

No.	Name and Description	Package size	Quantity
1.	<b>Anti-human CD71 monoclonal antibody</b> <ul style="list-style-type: none"> <li>• Isotype: Mouse IgG1</li> <li>• Clone: HI166</li> <li>• Buffer: PBS containing 1 % BSA and 0.09 % sodium azide (pH 7.2)</li> <li>• The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) (excitation at ~491nm, emission at ~516nm) under optimum conditions</li> </ul>	500uL	1

#### Part 2

No.	Name and Description	Package size	Quantity
1.	<b>Microbead kit</b> <ul style="list-style-type: none"> <li>• For positive selection of CD34+ hematopoietic stem and progenitor cells in a single step</li> <li>• CD34+ cells can be isolated from: peripheral blood (PBMCs), bone marrow, leukapheresis product, cord blood, differentiated ES and iPS cell lines</li> <li>• Application: Flow cytometric analysis, expansion in culture, in vitro differentiation</li> <li>• Size: 2x10<sup>9</sup> total cells</li> </ul>	1 kit	1

2.	<b>MS Columns</b> <ul style="list-style-type: none"> <li>For positive selection of cells</li> <li>Suitable for depletion of strongly magnetically labeled cells</li> <li>The column matrix of the MS Columns is composed of ferromagnetic spheres, which are covered with a cell-friendly coating allowing fast and gentle separation of cells</li> <li>Can be used to separate material less than 30 µm in size</li> <li>Individually packed in a sterile way</li> </ul>	25 pieces	3
3.	<b>30µm pre-separation filters, sterile</b> <ul style="list-style-type: none"> <li>For the easy removal of cell aggregates or large particles from single-cell suspensions for effective magnetic or fluorescent cell labeling, and thus optimal flow within cell separation columns and flow cytometer</li> <li>Filters fit onto tubes with a capacity of 5mL and 15 mL</li> </ul>	50 pieces	1
4.	<b>LS Columns</b> <ul style="list-style-type: none"> <li>For positive selection of cells</li> <li>Suitable for the depletion of strongly magnetically labeled cells</li> <li>Matrix of the LS Columns composed of ferromagnetic spheres, which are covered with a cell-friendly coating</li> <li>LS Columns can be used to separate material less than 30 µm in size</li> <li>Individually packed in a sterile way</li> </ul>	25 pieces	1
5.	<b>Dead cell removal kit</b> <ul style="list-style-type: none"> <li>Eliminates dead cells from cell culture or tissue preparations</li> <li>Kit contains microbeads and binding buffer for the magnetic labeling of cell debris, dead cells, and dying cells</li> <li>The magnetically labeled material is removed by magnetic separation and pure, viable cells are obtained within 25 minutes</li> <li>Size: 1x10<sup>9</sup> total cells</li> </ul>	1 pack	1
6.	<b>Microbeads, human</b> <ul style="list-style-type: none"> <li>For the positive selection or depletion of leukocytes from peripheral blood, erythrocyte and thrombocyte preparations, lymphoid tissues, as well as nonhematopoietic tissues</li> <li>Size: 1x10<sup>9</sup> total cells</li> </ul>	1 pack	1

### Part 3

No.	Name and Description	Package size	Quantity
1.	<b>Animal component-free, defined cryopreservation medium with 10% DMSO</b> <ul style="list-style-type: none"> <li>Ready-to-use</li> <li>Serum-free and protein-free</li> <li>Animal component-free</li> <li>Sterility, endotoxin, and cell-based quality control testing</li> <li>Cell/samples type: myeloma cell lines, human pluripotent stem cells, blood-derived cells</li> <li>Species: Human, Mouse, Non-Human Primate, Rat</li> </ul>	50mL	1
2.	<b>Serum-free medium for culture and expansion of hematopoietic cells</b> <ul style="list-style-type: none"> <li>Contains: Iscove's MDM, Bovine serum albumin, Recombinant human insulin, Human transferrin (iron-saturated), 2-Mercaptoethanol, Supplements</li> <li>Species: Human</li> <li>Cell type: Hematopoietic Stem and Progenitor Cells</li> </ul>	500mL	8
3.	<b>Supplement for serum-free cell culture media</b> <ul style="list-style-type: none"> <li>Contains bovine serum albumin (BSA), insulin, and transferrin (BIT) in Iscove's MDM</li> <li>Suitable for the culture of mouse hematopoietic progenitor cells in serum-free conditions</li> <li>Species: Human, Mouse</li> </ul>	100mL	5

**Part 4**

No.	Name and Description	Package size	Quantity
1.	<p><b>Anti-human CD45 monoclonal antibody</b></p> <ul style="list-style-type: none"> <li>• Isotype: mouse IgG1, κ</li> <li>• Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA</li> <li>• The antibody was purified by affinity chromatography and conjugated with PE (Excitation Laser: Blue Laser (~488 nm), Green Laser (~532 nm)/Yellow-Green Laser (~561 nm)) under optimal conditions</li> </ul>	100 tests	1
2.	<p><b>Anti-human CD34 monoclonal antibody</b></p> <ul style="list-style-type: none"> <li>• Isotype: mouse IgG2a, κ</li> <li>• Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA</li> <li>• The antibody was purified by affinity chromatography and conjugated with dye (that excites at ~405 nm and emits at ~421 nm) under optimal conditions</li> </ul>	100 tests	1
3.	<p><b>Anti-human CD38 monoclonal antibody</b></p> <ul style="list-style-type: none"> <li>• Isotype: mouse IgG1, κ</li> <li>• Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA</li> <li>• The antibody was purified by affinity chromatography and conjugated with dye (that excites at ~566 nm and emits at ~610 nm) under optimal conditions</li> </ul>	100 tests	1
4.	<p><b>Anti-human CD33 monoclonal antibody</b></p> <ul style="list-style-type: none"> <li>• Isotype: mouse IgG1, κ</li> <li>• Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA</li> <li>• The antibody was purified by affinity chromatography and conjugated with dye (that excites at ~482 nm and emits at ~690 nm) under optimal conditions</li> </ul>	100 tests	1
5.	<p><b>Anti-human CD45RA monoclonal antibody</b></p> <ul style="list-style-type: none"> <li>• Isotype: mouse IgG2b, κ</li> <li>• Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA</li> <li>• The antibody was purified by affinity chromatography and conjugated with dye (that excites at ~633 nm – red laser) under optimal conditions</li> </ul>	100 tests	1
6.	<p><b>Anti-human CD11b monoclonal antibody</b></p> <ul style="list-style-type: none"> <li>• Isotype: mouse IgG1, κ</li> <li>• Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA</li> <li>• The antibody was purified by affinity chromatography and conjugated with dye (Excitation Laser: Blue Laser (~488 nm), Green Laser (~532 nm)/Yellow-Green Laser (~561 nm)) under optimal conditions</li> </ul>	100 tests	1
7.	<p><b>Anti-human CD14 monoclonal antibody</b></p> <ul style="list-style-type: none"> <li>• Isotype: mouse IgG1, κ</li> <li>• Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA</li> <li>• The antibody was purified by affinity chromatography and conjugated with dye (that excites at ~488 nm – blue laser) under optimal conditions</li> </ul>	100 tests	1

**Part 5**

No.	Name and Description	Package size	Quantity
1.	<p><b>Mouse anti-human CD45 antibody</b></p> <ul style="list-style-type: none"> <li>• Isotype: Mouse IgG1, κ</li> <li>• Immunogen: Human Peripheral Blood Leucocytes</li> <li>• Volume per test: 5uL</li> <li>• Storage Buffer: Aqueous buffered solution containing BSA and ≤0.09% sodium azide</li> <li>• Conjugated with dye that has excitation max at ~496nm, ~566nm and emission max at ~781nm</li> <li>• Application: Flow cytometry</li> </ul>	100 tests	1

2.	<b>Human Fc Block</b> <ul style="list-style-type: none"> <li>• Reactivity: human, rhesus</li> <li>• Isotype: human IgG1</li> <li>• Concentration: 0.5 mg/mL</li> <li>• Storage buffer: aqueous buffered solution containing ≤0.09% sodium azide</li> <li>• Application: flow cytometry</li> </ul>	0,25mg	1
----	---	--------	---

### Part 6

No.	Name and Description	Package size	Quantity
1.	<b>Antibody Compensation Bead Kit</b> <ul style="list-style-type: none"> <li>• Provides a consistent, accurate, and simple-to-use technique for the setting of flow cytometry compensation when using fluorochrome-conjugated mouse, rat, hamster, or rabbit antibodies with any laser in flow cytometry</li> <li>• Detection method: Fluorescent</li> <li>• Diameter: 6µm</li> <li>• Contains: 1 vial of Compensation capture beads and 1 vial of negative beads</li> <li>• Format: tube</li> </ul>	100 tests	1
2.	<b>Amine Reactive Compensation Bead Kit</b> <ul style="list-style-type: none"> <li>• The kit includes two types of specially modified polystyrene microspheres that have been optimized to react with the amine-reactive dye</li> <li>• Detection method: Fluorescent</li> <li>• Diameter: 6µm</li> <li>• Excitation Wavelength Range: any laser (UV to 633/635)</li> <li>• Contains: 1 vial of amine reactive beads and 1 vial of negative beads</li> <li>• Format: tube</li> </ul>	20 tests	1
3.	<b>Human TPO (Thrombopoietin) Recombinant Protein</b> <ul style="list-style-type: none"> <li>• Species: Human</li> <li>• Expression system: E.coli</li> <li>• Amino acid sequence: SPAPPACDLR VLSKLLRDSH VLHSRLSQCP EVHPLPTPVL LPAVDLFSLGE WKTQMEETKA QDILGAVTLL LEGVMAARGQ LGPTCLSSLL QQLSGQVRLI LGALQSLLGT QLPPQGRITTA HKDPNAIFLS FQHLLRGKVR FLMLVGGSTL CVRRAPPTTA VPSRTSLVLT LNEL</li> <li>• Purity: ≥ 98% by SDS-PAGE gel and HPLC analyses</li> <li>• Endotoxin concentration: &lt;1 EU/µg</li> <li>• Unconjugated</li> </ul>	50 ug	1
4.	<b>Human Flt-3 Ligand (FLT3L) Recombinant Protein</b> <ul style="list-style-type: none"> <li>• Species: Human</li> <li>• Expression system: E.coli</li> <li>• Amino acid sequence: TQDCSFQHSP ISSDFAVKIR ELSDYLLQDY PVTVASNLQD EELCGGLWRL VLAQRWMERL KTVAGSKMQG LLERVNTEIH FVTKCAFQPP PSCLRFVQTN ISRLQETSE QLVALKPWIT RQNFSCRLEL QCQPDSSTLP PPWSPRPLEA TAPTA</li> <li>• Purity: ≥ 98% by SDS-PAGE gel and HPLC analyses.</li> <li>• Endotoxin concentration: &lt;1 EU/µg</li> <li>• Unconjugated</li> </ul>	100 ug	1
5.	<b>Human SCF Recombinant Protein</b> <ul style="list-style-type: none"> <li>• Species: Human</li> <li>• Expression system: E.coli</li> <li>• Amino acid sequence: MEGICRNRVT NNVKDVTKLV ANLPKDYMIT LKYVPGMDVL PSHCWISEMV VQLSDSLTDL LDKFSNISEG LSNYSIIDKL VNIVDDLVEC VKENSSKDLK KSFKSPEPRL FTPEEFFRIF NRSIDAFKDF VVASETSDCV VSSTLSPEKD SRVSVTKPFM LPPVA</li> <li>• Purity: ≥ 98% by SDS-PAGE gel and HPLC analyses.</li> <li>• Endotoxin concentration: &lt;1 EU/µg</li> <li>• Unconjugated</li> </ul>	250 ug	1

6.	<b>Human IL-3 Recombinant Protein</b> <ul style="list-style-type: none"> <li>Species: Human</li> <li>Expression system: E.coli</li> <li>Amino acid sequence: APMTQTTSLK TSWVNCSNMI DEIITHLKQP PLPLDFNNL</li> <li>NGEDQDILME NNLRRPNLEA FNRAVKSLQN ASAIESILKN LLPCLPLATA APTRHPIHIK</li> <li>DGDWNEFRRK LTFYKLTLEN AQAQQTLSL AIF</li> <li>Purity: ≥ 98% by SDS-PAGE gel and HPLC analyses.</li> <li>Endotoxin concentration: &lt;1 EU/μg</li> <li>Unconjugated</li> </ul>	50 ug	1
7.	<b>Human G-CSF Recombinant Protein</b> <ul style="list-style-type: none"> <li>Species: Human</li> <li>Expression system: E.coli</li> <li>Amino acid sequence:</li> <li>TPLGASSLP QSFLKCLEQ VRKIQGDGAA LQEKLCATYK LCHPEELVLL GHSLGIPWAP</li> <li>LSSCPSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG PTLDTLQLDV ADFATTIWQQ</li> <li>MEELGMAPAL QPTQGAMPAF ASAFQRRAGG VLVASHLQSF LEVSYRVLRLH LAQP</li> <li>Purity: ≥ 98% by SDS-PAGE gel and HPLC analyses.</li> <li>Endotoxin concentration: &lt;1 EU/μg</li> <li>Unconjugated</li> </ul>	50 ug	1

### Part 7

No.	Name and Description	Package size	Quantity
1.	<b>Recombinant Human IL-6 Protein</b> <ul style="list-style-type: none"> <li>Source: E.coli</li> <li>Purity: &gt;97%, by SDS-PAGE under reducing conditions and visualized by silver stain</li> <li>Endotoxin level: &lt;0.10 EU per 1 μg</li> <li>N-terminal sequence Analysis: Pro29</li> <li>Formulation: Lyophilized from a 0.2 μm filtered solution in PBS and NaCl with BSA as a carrier protein</li> <li>Reconstitute at 100-200 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin</li> </ul>	10 ug	2

### Part 8

No.	Name and Description	Package size	Quantity
1.	<b>Serum-free Hematopoietic Cell Medium</b> <ul style="list-style-type: none"> <li>Support the generation of LAK cells in a serum-free environment</li> <li>With L-Glutamine, gentamicin and phenol red, xenofree</li> <li>Superior media for most hematopoietic cells types including dendritic cells, lymphocytes, monocytes, macrophages and granulocytes</li> <li>Applications: Proliferation of peripheral blood lymphocytes, Proliferation of tumor infiltrating lymphocytes, Cryopreservation of human tissue, Cultivation of human monocytes and macrophages</li> </ul>	1L	2

- Offers submitted for products in packaging sizes other than those indicated above will be rejected.
- It is possible to make an offer for a part of an order (8 parts).
- Rules of order execution:
  - Place of delivery - the seat of the Ordering Party.
  - Delivery date – up to 21 calendar days from the date of delivery of the order; If range of time given, the upper value will be considered; Offers indicating a longer period will be rejected.

### III. PLACE, DATE AND PROCEDURE OF SUBMISSION OF QUOTES

- III.1. The offer must be submitted by: **28<sup>th</sup> September 2023 at 23.59 CET.**
- III.2. The offer must be sent via e-mail to the following address: [tenders@ryvu.com](mailto:tenders@ryvu.com). The message with the offer should refer to the RFQ number indicated on the first page: **AMB-21 09 2023 F.**
- III.3. The offer and its attachments should be prepared in Polish or English.

**III.4.** The quote should include the validity period (minimum 28 calendar days from the date of submission). The Ordering Party may require Bidders to agree to an extension of the quote validity period for the period of up to next 30 calendar days.

#### **IV. CRITERIA FOR EVALUATION OF QUOTES**

**IV.1.** Offers that comply with the order description (set out in section II.) will be accepted for the evaluation of offers. Offers that do not meet the requirements will be rejected.

**IV.2.** Criterion: Net price ("C") – weight: 100% (10 points)

**IV.3.** Net price ("C") is considered as the total price for the execution of the order (purchase and delivery).

**IV.4.** Due to the possibility of submitting offers in parts, the Ordering Party allows more than one offer to be selected.

**IV.5.** As regards prices quoted in foreign currencies, in order to compare the offers they shall be converted into PLN at the average exchange rate of the National Bank of Poland (NBP) prevailing on the day of closing the tender procedure indicated in section IV.1.

**IV.6.** In the Net Price criterion, points will be awarded (to two decimal places) according to the formula:

$$\text{Criterion Net price "C"} = \frac{\text{the lowest net price offered among the bids submitted}}{\text{net price of the examined offer}} \times 10 \text{ points}$$

**IV.7.** The Ordering Party will select as the most advantageous the offer that obtains the highest number of point.

**IV.8.** Having to choose between quotation scored in the same number of points, the Ordering Party will call Bidders to re-present the prices.

#### **V. ADDITIONAL INFORMATION**

**V.1.** The Bidders may ask the Ordering Party to clarify the content of this Quote Request. If the request for clarification of the content of the RFQ was received later than by the end of 25<sup>th</sup> September 2023, the Ordering Party may provide explanations or leave the application unexamined. Questions must be sent to the following e-mail address: [tenders@ryvu.com](mailto:tenders@ryvu.com).

**V.2.** The Ordering Party reserves the right to change the content of the RFQ, including changes in the terms of the procedure. Bidders will be informed.

**V.3.** The Ordering Party reserves the right to ask the Bidders at any stage of the evaluation of offers for additional information, documents, additions or explanations. The Ordering Party's contact with the Bidder will take place by e-mail indicated in the content of the offer sent by the Bidder.

**V.4.** The Ordering Party reserves the right to close the procedure without selecting any of the offers or to cancel the procedure at any stage.

**V.5.** This RFQ does not oblige the Ordering Party to conclude a contract.

**V.6.** For more information, please contact Aleksandra Broda at the following email address: [tenders@ryvu.com](mailto:tenders@ryvu.com).